PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000975296.46536.6a |
| _version_ | 1797281526470148096 |
|---|---|
| author | Katja Weisel Vania Hungria Hang Quach Sung-Soo Yoon Paula Rodríguez-Otero Glenn Kroog Arijit Sinha Anita Boyapati Charlotte Lyon Karen Rodriguez Lorenc Timothy Inocencio James Harnett Lei Chi Vygngley Moore Peter Voorhees |
| author_facet | Katja Weisel Vania Hungria Hang Quach Sung-Soo Yoon Paula Rodríguez-Otero Glenn Kroog Arijit Sinha Anita Boyapati Charlotte Lyon Karen Rodriguez Lorenc Timothy Inocencio James Harnett Lei Chi Vygngley Moore Peter Voorhees |
| author_sort | Katja Weisel |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:58:47Z |
| format | Article |
| id | doaj.art-331bd93f48144d34a96f1aff164681fb |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:58:47Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-331bd93f48144d34a96f1aff164681fb2024-03-03T03:25:51ZengWileyHemaSphere2572-92412023-08-017e465366a10.1097/01.HS9.0000975296.46536.6a202308003-01998PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)Katja Weisel0Vania Hungria1Hang Quach2Sung-Soo Yoon3Paula Rodríguez-Otero4Glenn Kroog5Arijit Sinha6Anita Boyapati7Charlotte Lyon8Karen Rodriguez Lorenc9Timothy Inocencio10James Harnett11Lei Chi12Vygngley Moore13Peter Voorhees141 University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Clinica São Germano and Santa Casa Medical School, Department of Hematology, São Paulo, Brazil3 St. Vincent’s Hospital Melbourne, University of Melbourne, Melbourne, Australia4 Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Korea, Rep. of South5 Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red Cáncer, Pamplona, Spain6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States7 Regeneron UK Ltd., Uxbridge, United Kingdom6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States8 Levine Cancer Institute, Charlotte, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000975296.46536.6a |
| spellingShingle | Katja Weisel Vania Hungria Hang Quach Sung-Soo Yoon Paula Rodríguez-Otero Glenn Kroog Arijit Sinha Anita Boyapati Charlotte Lyon Karen Rodriguez Lorenc Timothy Inocencio James Harnett Lei Chi Vygngley Moore Peter Voorhees PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) HemaSphere |
| title | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_full | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_fullStr | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_full_unstemmed | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_short | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_sort | pb2133 trial in progress linker mm3 a phase 3 open label randomized study of linvoseltamab versus elotuzumab pomalidomide and dexamethasone epd in relapsed refractory multiple myeloma rrmm |
| url | http://journals.lww.com/10.1097/01.HS9.0000975296.46536.6a |
| work_keys_str_mv | AT katjaweisel pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT vaniahungria pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT hangquach pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT sungsooyoon pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT paularodriguezotero pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT glennkroog pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT arijitsinha pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT anitaboyapati pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT charlottelyon pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT karenrodriguezlorenc pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT timothyinocencio pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT jamesharnett pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT leichi pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT vygngleymoore pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT petervoorhees pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm |